BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33524900)

  • 1. Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial.
    Ikeda S; Kudo M; Izumi N; Kobayashi M; Azuma M; Meier G; Pan J; Ishii M; Kaneko S
    Value Health Reg Issues; 2021 May; 24():82-89. PubMed ID: 33524900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
    Kobayashi M; Kudo M; Izumi N; Kaneko S; Azuma M; Copher R; Meier G; Pan J; Ishii M; Ikeda S
    J Gastroenterol; 2019 Jun; 54(6):558-570. PubMed ID: 30788569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
    Kim JJ; McFarlane T; Tully S; Wong WWL
    Oncologist; 2020 Mar; 25(3):e512-e519. PubMed ID: 32162815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective.
    Meyers BM; Vogel A; Marotta P; Kavan P; Kamboj L; Pan J; Geadah M; Trueman D; Sabapathy S
    Can J Gastroenterol Hepatol; 2021; 2021():8811018. PubMed ID: 33681090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
    Saiyed M; Byrnes J; Srivastava T; Scuffham P; Downes M
    Clin Drug Investig; 2020 Dec; 40(12):1167-1176. PubMed ID: 33140194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
    Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
    Cai H; Zhang L; Li N; Zheng B; Liu M
    J Comp Eff Res; 2020 Jun; 9(8):553-562. PubMed ID: 32419473
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
    Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
    Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
    Yamashita T; Kudo M; Ikeda K; Izumi N; Tateishi R; Ikeda M; Aikata H; Kawaguchi Y; Wada Y; Numata K; Inaba Y; Kuromatsu R; Kobayashi M; Okusaka T; Tamai T; Kitamura C; Saito K; Haruna K; Okita K; Kumada H
    J Gastroenterol; 2020 Jan; 55(1):113-122. PubMed ID: 31720835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
    Meng R; Zhang X; Zhou T; Luo M; Qiu Y
    Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1079-1086. PubMed ID: 35579405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
    Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
    Finn RS; Kudo M; Cheng AL; Wyrwicz L; Ngan RKC; Blanc JF; Baron AD; Vogel A; Ikeda M; Piscaglia F; Han KH; Qin S; Minoshima Y; Kanekiyo M; Ren M; Dairiki R; Tamai T; Dutcus CE; Ikezawa H; Funahashi Y; Evans TRJ
    Clin Cancer Res; 2021 Sep; 27(17):4848-4858. PubMed ID: 34108184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma.
    Briggs A; Daniele B; Dick K; Evans TRJ; Galle PR; Hubner RA; Lopez C; Siebert U; Tremblay G
    Br J Cancer; 2020 Jun; 122(12):1754-1759. PubMed ID: 32265508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
    Zhou T; Wang X; Cao Y; Yang L; Wang Z; Ma A; Li H
    BMC Health Serv Res; 2022 Nov; 22(1):1367. PubMed ID: 36397064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib mesylate to treat hepatocellular carcinoma.
    Ielasi L; Tovoli F; Piscaglia F
    Drugs Today (Barc); 2019 May; 55(5):305-313. PubMed ID: 31131841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
    Casadei-Gardini A; Scartozzi M; Tada T; Yoo C; Shimose S; Masi G; Lonardi S; Frassineti LG; Nicola S; Piscaglia F; Kumada T; Kim HD; Koga H; Vivaldi C; Soldà C; Hiraoka A; Bang Y; Atsukawa M; Torimura T; Tsuj K; Itobayashi E; Toyoda H; Fukunishi S; Rimassa L; Rimini M; Cascinu S; Cucchetti A
    Liver Int; 2021 Jun; 41(6):1389-1397. PubMed ID: 33547848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
    Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
    J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.